EP0062

PreclinicalSmall molecule

EEllipses Pharma

EP0062 is one of 34 small molecule programs targeting Breast Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Hormone-Receptor-Positive Breast CancerRecruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Hormone-Receptor-Positive Breast CancerPreclinical

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Adenocard

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

Acupan

YYonsei University

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Systemic Therapy

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Hormone-Receptor-Positive Breast Cancer

NCT05573126

Clinical

Trials by Indication[1]

Hormone-receptor-positive Breast Cancer1 trial

A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting·EEllipses Pharma·Preclinical·NCT05573126·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EP0062. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EP0062 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EP0062. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ellipses Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEllipses Pharma

EP0062

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hormone-receptor-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News